$LLY

$LLY · Schwab Network · 2026-11-12

AI 摘要 · Schwab Network

Eli Lilly 技术面强劲,说话者预计将出现一段有节制的上行:较快的移动平均线有利于多头,但该股尚未令人信服地突破 14.50 的上限,且 RSI 显示看跌背离。他更倾向于用期权结构在捕捉上行空间的同时限制下行风险,目标 1560–1600,理想涨幅 8–10%;该股估值偏高、期权操作难度大,而医疗保健板块到 2027 年应保持相对强势。

看涨他说的是几个月内
《The Big 3: JNJ, LLY, AAPL》
Schwab Network发布 2026-11-12 · 6 段内容

播放时,YouTube 可能接收设备与播放信息并使用 Cookie。 隐私说明 · Google 隐私政策

06:05/ —打开原视频

逐段跳播

6 段内容
6:0511:18

你的下一个选择也在医疗保健板块。我们有 Eli Lilly。我是说,也许 Eli Lilly 的图表在技术面上更清晰。那么,你对 Lilly 的前景怎么看?观点类似。从技术角度看,动量肯定是在的。

但同样,我从根本上认为,随着我们进入2027年,医疗保健板块将继续展现出相对强度。这是一只昂贵的股票。由于股票的规模和期权的成本,很难在它上面构建期权头寸。不过,我仍然相信有机会,这就是为什么我今天看交易示例时,重点是在期权上构建一笔交易。

因此,在某种程度上,我们识别下行风险,同时具备捕捉价格上涨的能力。

Your next choice is also in the healthcare sector. We have Eli Lilly. I mean, perhaps Eli Lilly's chart is more technically clear. So , what is your outlook for Lilly? A similar view.

The momentum is definitely there from a technical standpoint. But again, I fundamentally believe that the healthcare sector will continue to demonstrate relative strength as we enter 2027.

It is an expensive stock. It is difficult to structure options positions on it due to the size of the stock and the cost of the options as well. However, I still believe there are opportunities, and that's why when I looked at the trading example today, the focus was on structuring a deal around options.

Therefore, to some extent, we identify downside risks with the ability to capture upward price movements.

好。我们来看看这个箭头。Rick,从图表判断,趋势在这里似乎也对你有有利,而且有一系列利好消息推动它上涨,包括在中国的获批。他们现在用“Fondo”这种药物治疗睡眠呼吸暂停。我是说,这只股票有很多潜在的正向进展。但你在技术准备中看到了什么?

Good. Let's take a look at this arrow. Rick, judging from the chart, the trend seems to be in your favor here as well, and there has been a series of positive news events pushing it upwards, including the approval in China.

They are now treating sleep apnea with the drug "Fondo". I mean, there are a lot of potential positive developments for this name. But what do you see in the technical preparation?

这里又是一张强劲的图表。正如我们提到的,是类似的公司。这只股票从我们记录到的接近8.50的低位上涨了70%。但整体来看,过去一年,也就是过去251个交易日,它的涨幅与Johnson & Johnson相近,即上涨了42%。

所以,我们再次在今天创下了52周新高。这个水平达到了14.60。但我们在突破这一系列高点时遇到了一些困难,也就是我们在接近14.50处看到的这个天花板。我们还没有看到强劲且令人信服的上行突破。

今天仍处于早期阶段。本周我们还有一个交易日。所以一切皆有可能。但就目前而言,这只股票似乎在这里稍作休整。这里还有几个交易者可能想关注的简单水平位。13.30,这是我们向上跳空后的低点,以及我们随后在同一水平附近达到的低点。

我们的跳空缺口也大约在1300水平处打开。同样,这里在1230和1215处也有缺口,位置稍低一些,但基于我们的缺口和水平位,这是一个类似的关注区域。目前,我们深蓝色的5日指数移动平均线大约在14.25。

所以如果我们下行并跌破这条短期移动平均线,我们青绿色的21日指数移动平均线大约在13.50。那会略低于我们的趋势线。但如果你持乐观态度,这里的移动平均线正是你想看到的。较快的均线全部强于较慢的均线。

它们彼此都在发散,表明趋势仍然有利于多头,我们可以看到相对强弱指数(RSI),也就是我们的动量指标,可能显示出略有不同的读数。我们处于超买区,但尽管价格上涨,我们同时也在录得更低的峰值。

所以,这是一个相当混杂的信号。一方面,超买区是强势的信号,但我们这里有一点看跌背离。所以,要关注下降趋势线是否会被突破,尤其是如果我们开始在收盘时推动价格走向新的历史高点。我们的成交量分布显示,这里在13.95到14.40之间有一个小节点。

直到我们回到1190这个低位之前,成交量明显稀少。所以如果我们开始突破其中一些既定水平,你可能会看到更快的价格走势。最近交易也极其活跃,成交量出现了几次激增。

Another strong chart here. Similar companies, as we mentioned here. This stock has risen 70% from those low levels we recorded near 8.50. But over the past year as a whole, i.e., the past 251 trading days, it rose by a similar amount to Johnson & Johnson, i.e., an increase of 42%.

So, once again, we recorded our highest level in 52 weeks today. This level reached 14.60. But we had some difficulty getting past this series of highs, this ceiling that we saw close to 14.50.

We have yet to see a strong and convincing upward breakout here. Today is still in its early stages. We still have one more trading day this week. So, anything is possible. But for now, the stock seems to be taking a slight break here.

There are also a few easy horizontal levels that traders might want to watch here. 13.30, which is the low point after our upward gap, and the subsequent low point we reached around the same level here.

Our gap also opened up around the 1300 level. Similarly, there is a gap here at 1230 and 1215, which is a little further down , but it is a similar area to watch based on our gaps and horizontal levels .

Right now, our 5-day exponential moving average in dark blue is around 14.25. So if we move down and break below that short-term moving average , our 21-day exponential moving average in turquoise is around 13.50 here.

That would be slightly below our trend line . But the moving averages here are what you want to see if you're optimistic. The faster averages all outperform the slower ones. They are all diverging from each other, indicating that the trend is still in favor of the bulls here, and we can see that the Relative Strength Index ( RSI), our momentum measure, is probably showing a slightly different reading.

We are in the overbought zone, but we are also recording a lower peak despite the price increase. So, this is a rather mixed message here. On one hand, the overbought zone is a sign of strength, but we have a bit of a bearish divergence here.

So, watch to see if the downtrend line will be broken, especially if we start pushing the price towards new record highs on the close here. Our size profile shows that we have a small node here, between 13.95 and 14.40.

Things become noticeably scarce until we return to this low level at 1190. So you might see faster price action if we start to break through some of these established levels. There has been extremely heavy trading lately as well, with several surges in trading volumes here.

是的,我们现在在1447.77,所以就Eli Lilly这只股票而言,它是一家价格贵得多的公司。但是Dan,你在评估Eli Lilly股票时会看哪些具体的执行价格?

Yes, we are now at 1447.77, so it is a much more expensive company in terms of Eli Lilly stock. But Dan, what specific execution prices do you look at when you evaluate Eli Lilly stock?

是的,Marley,正如你指出的,这只股票价格在1400到1500美元之间,这一特性使得它在构建交易模型时很独特。但与此同时,我认为识别下行风险是看待这件事的一个方面。因此,今天的交易模型基于1460的执行价格,这是在1月份。

鉴于我们有更多时间,我们会买入一份执行价格为1460的合约,然后卖出一份1560的合约,再在其上方卖出一份1660的合约。这叫做“看涨树”。就是买入一份合约并卖出两份合约。这使盈亏平衡点降至约20美元,但同时为未来两个月的上行提供了很大的盈利区间。

当然,理想区间是上涨8%到10%,但这个形态上行的盈亏平衡点大约在1735。那意味着较当前交易价格上涨20%或更多。它当然能到那里,是的,但这里的思路是瞄准1560到1600之间的区域,这个模型允许这样做,同时以“期权树”的成本来识别下行风险。

Yes, again Marley, as you pointed out, the nature of this stock being priced at $1400 to $1500 makes it unique in terms of trying to structure a trading model. But at the same time, I think identifying downside risks was one aspect of looking at this.

Therefore, today’s trading model is based on an execution price of 1460, and this is in January. Given that we are given more time, we will buy a contract at an execution price of 1460, then sell a contract at 1560, and sell an additional contract above that at 1660.

It is called a " call tree". It is the purchase of one contract and the sale of two contracts. This reduces the breakeven point to around $20, but at the same time it gives a large profit zone for the upside over the next two months.

Certainly, the ideal range is an 8 to 10% rise, but the breakeven point on the upside of this pattern is around 1735. That would mean a rise of 20% or more from the price at which it is currently trading.

It can certainly reach there, yes, but the idea here is to target an area between the 1560 and 1600 levels, and this model allows for that while identifying downside risks at the cost of the "options tree".

好。那么我们现在Eli Lilly在1448,我们期待一次走势,一次有节制的上行。

Good. So we have Eli Lilly now at 1448, and we're looking forward to a move, a measured upward move here.

这个频道对 $LLY 的历次判断

Schwab Network 在这只股票上共 7 条判断,这里只列相邻的几条。

跨洋听风